Evidence map›Paper›PMID 39296083›Full record

ReviewHeliyon2024

Natural products for the treatment of hypertrophic scars: Preclinical and clinical studies.

Yuxiao Zhang, E Liu, Hongjin Gao, Qingying He, Anjing Chen, Yaobing Pang, Xueer Zhang, Sixian Bai, Jinhao Zeng, Jing Guo

Abstract readReview
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuxiao ZhangHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
E LiuHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Hongjin GaoChengdu First People's Hospital, China.
Qingying HeHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Anjing ChenHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Yaobing PangHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Xueer ZhangHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Sixian BaiHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Jinhao ZengHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.
Jing GuoHospital of Chengdu University of Traditional Chinese Medicine Department of Dermatology, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic scarring (HS) is a complication of wound healing that causes physiological and psychological distress in patients. However, the possible mechanism underlying HS is not fully understood, and there is no gold standard for its treatment. Natural products are more effective, economical, convenient, and safe than existing drugs, and they have a wide application prospect. However, there is a lack of literature on this topic, so we reviewed in vivo, in vitro, and clinical studies and screened natural products showing beneficial effects on HS that can become potential therapeutic agents for HS to fill in the gaps in the field. In addition, we discussed the drug delivery systems related to these natural products and their mechanisms in the treatment of HS. Generally speaking, natural products inhibit inflammation, myofibroblast activation, angiogenesis, and collagen accumulation by targeting interleukins, tumor necrosis factor-α, vascular endothelial growth factors, platelet-derived growth factors, and matrix metalloproteinases, so as to play an anti-HS effects of natural products are attributed to their anti-inflammatory, anti-proliferative, anti-angiogenesis, and pro-apoptotic (enhancing apoptosis and autophagy) roles, thus treating HS. We also screened the potential therapeutic targets of these natural compounds for HS through network pharmacology and constructed a protein-protein interaction (PPI) network, which may provide clues for the pharmacological mechanism of natural products in treating this disease and the development and application of drugs.

Indexed as

Drug discoveryHypertrophic scarsMechanismsNatural productsTraditional Chinese medicine

Identifiers

PMID39296083
PMCPMC11408005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.